Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia

Journal of Psychiatric Research

Volumn 61, Issue , 2015, Pages 64-72

  Xu, Ke ^a,c   Krystal, John H ^a,c   Ning, Yuping ^b   Chen, Da Chun ^f   He, Hongbo ^b   Wang, Daping ^b   Ke, Xiaoyin ^b   Zhang, Xifan ^d   Ding, Yi ^b   Liu, Yuping ^b   Gueorguieva, Ralitza ^a,e   Wang, Zuoheng ^e   Limoncelli, Diana ^c   Pietrzak, Robert H ^a,c   Petrakis, Ismene L ^a,c   Zhang, Xiangyang ^f   Fan, Ni ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d Guangzhou Mental Health Hospital   (China)

^e YALE UNIVERSITY   (United States)

^f PEKING UNIVERSITY   (China)

Author keywords

Factor analysis; Ketamine psychosis; Positive and Negative Syndrome Scale (PANSS); Schizophrenia; Symptom severity

Indexed keywords

KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; BLUNTED AFFECT; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DELUSION; DEPRESSION; DISEASE SEVERITY; DISORIENTATION; DRUG ABUSE; EXCITEMENT; FEMALE; HALLUCINATION; HAN CHINESE; HOSTILITY; HUMAN; KETAMINE ASSOCIATED PSYCHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISSOCIATION; MOTOR RETARDATION; NEGATIVE SYNDROME; PERSECUTORY DELUSION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; SCHIZOPHRENIA; SUSPICIOUSNESS; SYMPTOMATOLOGY; THINKING IMPAIRMENT; FACTORIAL ANALYSIS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOMETRY; PSYCHOTIC DISORDERS; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; EXCITATORY AMINO ACID ANTAGONISTS; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84921601336     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.12.012     Document Type: Article

References (53)

1. Abi-Saab W.M., D'Souza D.C., Moghaddam B., Krystal J.H. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998, 31(Suppl.2):104-109.
2. Adler C.M., Goldberg T.E., Malhotra A.K., Pickar D., Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 1998, 43:811-816.
3. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999, 156:1646-1649.
4. Aggarwal N.K., Tao H., Xu K., Stefanovics E., Zhening L., Rosenheck R.A. Comparing the PANSS in Chinese and American inpatients: cross-cultural psychiatric analyses of instrument translation and implementation. Schizophr Res 2011, 132:146-152.
5. Anticevic A., Cole M.W., Repovs G., Savic A., Driesen N.R., Yang G., et al. Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural system dysfunction in schizophrenia. Front Psychiatry 2013, 4:169.
6. Cannon C.E., Puri V., Vivian J.A., Egbertson M.S., Eddins D., Uslaner J.M. The nicotinic alpha7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. Neuropharmacology 2013, 64:191-196.
7. Chatterjee M., Verma R., Ganguly S., Palit G. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology 2012, 63:1161-1171.
8. Chen da C., Zhou M.A., Zhou D.H., Xiu M.H., Wu G.Y., Kosten T.R., et al. Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics. Psychiatry Res 2011, 186:451-453.
9. Coyle J.T., Tsai G., Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord 2002, 1:183-189.
10. Curran H.V., Monaghan L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001, 96:749-760.
11. Dawson N., McDonald M., Higham D.J., Morris B.J., Pratt J.A. Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks. Neuropsychopharmacology June 2014, 39(7):1786-1798. Epub 2014 Feb 4. 10.1038/npp.2014.26.
12. Dickerson D., Pittman B., Ralevski E., Perrino A., Limoncelli D., Edgecombe J., et al. Ethanol-like effects of thiopental and ketamine in healthy humans. JPsychopharmacol 2010, 24:203-211.
13. Driesen N.R., McCarthy G., Bhagwagar Z., Bloch M.H., Calhoun V.D., D'Souza D.C., et al. The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology 2013, 38:2613-2622.
14. Edward Roberts R., Curran H.V., Friston K.J., Morgan C.J. Abnormalities in white matter microstructure associated with chronic ketamine use. Neuropsychopharmacology 2014, 39:329-338.
15. Fauman B.J., Fauman M.A. Chronic phenycyclidine (PCP) abuse: a psychiatric perspective-Part II: psychosis [proceedings]. Psychopharmacol Bull 1980, 16:72-73.
16. Fine J., Finestone S.C. Sensory disturbances following ketamine anesthesia: recurrent hallucinations. Anesth Analg 1973, 52:428-430.
17. Frost D.O., Tamminga C.A., Medoff D.R., Caviness V., Innocenti G., Carpenter W.T. Neuroplasticity and schizophrenia. Biol Psychiatry 2004, 56:540-543.
18. Honey G.D., Corlett P.R., Absalom A.R., Lee M., Pomarol-Clotet E., Murray G.K., et al. Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo. JNeurosci 2008, 28:6295-6303.
19. Javitt D.C. Phenomenology, aetiology and treatment of schizophrenia. Novartis Found Symp 2008, 289:4-16. discussion 17-22, 87-93.
20. Javitt D.C., Zukin S.R., Heresco-Levy U., Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 2012, 38:958-966.
21. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
22. Jiang J., Sim K., Lee J. Validated five-factor model of positive and negative syndrome scale for schizophrenia in Chinese population. Schizophr Res 2013, 143:38-43.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
24. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Gueorguieva R., et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacol Berl 2005, 179:303-309.
25. Krystal J.H., D'Souza D.C., Karper L.P., Bennett A., Abi-Dargham A., Abi-Saab D., et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacol Berl 1999, 145:193-204.
26. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacol Berl 2003, 169:215-233.
27. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
28. Krystal J.H., Perry E.B., Gueorguieva R., Belger A., Madonick S.H., Abi-Dargham A., et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005, 62:985-994.
29. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
30. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25:455-467.
31. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
32. McGlashan T.H., Hoffman R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 2000, 57:637-648.
33. Moghaddam B., Jackson M.E. Glutamatergic animal models of schizophrenia. Ann N Y Acad Sci 2003, 1003:131-137.
34. Moghaddam B., Krystal J.H. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull 2012, 38:942-949.
35. Morgan C.J., Muetzelfeldt L., Curran H.V. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 2009, 104:77-87.
36. Morgan C.J., Muetzelfeldt L., Curran H.V. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010, 105:121-133.
37. Nikiforuk A., Kos T., Fijal K., Holuj M., Rafa D., Popik P. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One 2013, 8:e66695.
38. Patel A., Moreland T., Haq F., Siddiqui F., Mikul M., Qadir H., et al. Persistent psychosis after a single ingestion of "Ecstasy" (MDMA). Prim Care Companion CNS Disord 2011, 13.
39. Potash M.N., Gordon K.A., Conrad K.L. Persistent psychosis and medical complications after a single ingestion of MDMA "Ecstasy": a case report and review of the literature. Psychiatry (Edgmont) 2009, 6:40-44.
40. Scheidegger M., Walter M., Lehmann M., Metzger C., Grimm S., Boeker H., et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One 2012, 7:e44799.
41. Schobel S.A., Chaudhury N.H., Khan U.A., Paniagua B., Styner M.A., Asllani I., et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013, 78:81-93.
42. Stefanovics E.A., Elkis H., Zhening L., Zhang X.Y., Rosenheck R.A. Across-national factor analytic comparison of three models of PANSS symptoms in schizophrenia. Psychiatry Res 2014, 219:283-289.
43. Stone J.M., Pepper F., Fam J., Furby H., Hughes E., Morgan C., et al. Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacol Berl May 2013, 231(10):2107-2116. Epub 2013 Nov 22. 10.1007/s00213-013-3354-8.
44. Tang W.K., Liang H.J., Lau C.G., Tang A., Ungvari G.S. Relationship between cognitive impairment and depressive symptoms in current ketamine users. JStud Alcohol Drugs 2013, 74:460-468.
45. Tarabeux J., Kebir O., Gauthier J., Hamdan F.F., Xiong L., Piton A., et al. Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry 2011, 1:e55.
46. Timms A.E., Dorschner M.O., Wechsler J., Choi K.Y., Kirkwood R., Girirajan S., et al. Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 2013, 70:582-590.
47. Vollenweider F.X., Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010, 11:642-651.
48. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res 2012, 137:246-250.
49. Wiescholleck V., Manahan-Vaughan D. Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis. Neuropharmacology 2013, 74:48-58.
50. Zhang X.Y., Chen da C., Xiu M.H., Yang F.D., Haile C.N., Kosten T.A., et al. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. JClin Psychiatry 2012, 73:1025-1033.
51. Zhang Y., Lu C., Zhang J., Hu L., Song H., Li J., et al. Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China. Addict Behav 2013, 38:1424-1430.
52. Zhang Y., Xu Z., Zhang S., Desrosiers A., Schottenfeld R.S., Chawarski M.C. Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China. JPsychiatr Res 2014, 53:99-102.
53. Zugno A.I., de Miranda I.M., Budni J., Volpato A.M., Luca R.D., Deroza P.F., et al. Effect of maternal deprivation on acetylcholinesterase activity and behavioral changes on the ketamine-induced animal model of schizophrenia. Neuroscience 2013, 248C:252-260.